RBRoger Belusa

Roger Belusa

*This is an algorithmically generated author record based on publicly available information.

Roger Belusa has a total of 20 co-authors. Here are the top co-authors by number of shared publications:

  • Espen Thiis-Evensen

    Department of Gastroenterology ENETS Neuroendocrine Tumor Centre of Excellence Oslo University Hospital, Rikshospitalet Oslo Norway

    2 shared publications
  • Magnus Kjellman

    Department of Breast, Endocrine Tumors and Sarcoma Karolinska University Hospital Solna Stockholm Sweden

    2 shared publications
  • Staffan Welin

    Department of Endocrine Oncology Uppsala University Hospital, ENETS Center of Excellence Uppsala Sweden

    2 shared publications
  • The Nordic NET Biomarker Group

    2 shared publications
  • A. C. Eklof

    Department of Woman and Child Health, St. Goran's Children's Hospital,Karolinska Institute, Stockholm, Sweden

    1 shared publication
  • Anita Aperia

    Department of Women's and Children's Health, Science for Life Laboratory, Karolinska Institutet, Stockholm, Sweden

    1 shared publication

Latest Publications

  • Open Access

    Association rule mining of clinical and biomarker data in neuroendocrine tumors: A prospective study on disease progression

    by Ulrich Peter Knigge, Magnus Kjellman, Henning Grønbæk, Espen Thiis‐Evensen, Camilla Schalin‐Jäntti, Staffan Welin, Halfdan Sørbye, Maria del Pilar Schneider, Roger Belusa, The Nordic NET Biomarker Group

    There is an unmet need for new methods to predict disease course in patients with neuroendocrine tumors (NET). We investigated 92 putative cancer‐related plasma proteins including chromogranin A (CgA) and clinical parameters at the time of diagnosis to identify early factors associated with progressive (PD) or stable disease (SD). Patients with NET grade 1 and 2 of the small intestine (siNET) and pancreas (pNET) were included in this prospective study. Blood samples were obtained at the time of diagnosis before tumor‐related therapy was initiated. During 3 years of follow‐up, SD or PD was determined according to current clinical practice by each investigator. Association rule mining (ARM) was used to identify combinations of biomarkers and clinical parameters associated with SD or PD. Altogether, 115 patients with siNET and 30 with pNET with complete clinical and biomarker data were included in the analysis representing 3 years of follow‐up. Several novel plasma proteins and clinical factors were associated with either PD or SD. In siNET, CgA (>4 upper limits of normal [ULN]) was the most frequent biomarker associated with PD. Females, in contrast to males, with CgA >4 ULN showed a high risk of progression (PPV 100%, NPV 63%). In the siNET cohort, Carboxypeptidase E (CPE) was a discriminating factor between SD and PD. CPE 3.14 was associated with PD (p = 0.003). In the pNET cohort, among clinical variables, only the presence of liver metastasis was associated with PD. CgA was not among the top biomarkers associated with PD. Several parameters, both clinical and biomarker data, as well as combinations of these, were associated with PD or SD 3 years after diagnosis. We identified novel biomarkers improving the association with PD or SD. [Correction added on 28 August 2025, after first online publication: Abstract has been updated.]


  • Open Access

    Plasma protein biomarkers for the detection of pancreatic neuroendocrine tumors and differentiation from small intestinal neuroendocrine tumors

    by Espen Thiis‐Evensen, Magnus Kjellman, Ulrich Knigge, Henning Gronbaek, Camilla Schalin‐Jäntti, Staffan Welin, Halfdan Sorbye, Maria del Pilar Schneider, Roger Belusa, The Nordic NET Biomarker Group

    There is an unmet need for novel biomarkers to diagnose and monitor patients with neuroendocrine neoplasms. The EXPLAIN study explores a multi‐plasma protein and supervised machine learning strategy to improve the diagnosis of pancreatic neuroendocrine tumors (PanNET) and differentiate them from small intestinal neuroendocrine tumors (SI‐NET). At time of diagnosis, blood samples were collected and analyzed from 39 patients with PanNET, 135 with SI‐NET (World Health Organization Grade 1–2) and 144 controls. Exclusion criteria were other malignant diseases, chronic inflammatory diseases, reduced kidney or liver function. Prosed Oncology‐II (i.e., OLink) was used to measure 92 cancer related plasma proteins. Chromogranin A was analyzed separately. Median age in all groups was 65–67 years and with a similar sex distribution (females: PanNET, 51%; SI‐NET, 42%; controls, 42%). Tumor grade (G1/G2): PanNET, 39/61%; SI‐NET, 46/54%. Patients with liver metastases: PanNET, 78%; SI‐NET, 63%. The classification model of PanNET versus controls provided a sensitivity (SEN) of 0.84, specificity (SPE) 0.98, positive predictive value (PPV) of 0.92 and negative predictive value (NPV) of 0.95, and area under the receiver operating characteristic curve (AUROC) of 0.99; the model for the discrimination of PanNET versus SI‐NET providing a SEN 0.61, SPE 0.96, PPV 0.83, NPV 0.90 and AUROC 0.98. These results suggest that a multi‐plasma protein strategy can significantly improve diagnostic accuracy of PanNET and SI‐NET.


  • Development of urinary concentrating capacity: role of aquaporin-2

    by M. Yasui, D. Marples, R. Belusa, A. C. Eklof, G. Celsi, S. Nielsen, A. Aperia

    The capacity to concentrate urine develops progressively during postnatal life in most mammalian species. Here we have examined whether low expression of the arginine vasopressin (AVP)-activated water channel aquaporin-2 (AQP-2) may be a limiting factor for the concentrating capacity in the infant rats. Urine osmolality in response to 24-h dehydration increased significantly from 10 to 40 days of age. The most rapid increase occurred during the weaning period, i.e., days 15-20. A similar developmental pattern was observed for AQP-2 mRNA levels in the renal medulla. AQP-2 protein levels also increased markedly from day 10 to 40. Immunohistochemistry revealed that AQP-2 was exclusively located in collecting duct principal cells both in infant and adult rats but that the signal was much weaker in infants. To further examine the relationship between urinary concentrating capacity and AQP-2 expression, we treated rats with a single injection of betamethasone, which is known to accelerate maturation in several organs. Twenty-four hours after treatment, there was an increase in urine osmolality, renal medullary AQP-2 mRNA, and AQP-2 protein levels in infant but not in adult rats. A single injection of a specific V2 agonist caused within 6 h significant increase of AQP-2 mRNA in both infant and adult. The expression of the mRNA of three other transporters involved in the concentrating process, medullary Na(+)-K(+)-ATPase alpha-subunit, Na-K-2Cl cotransporter, and epithelial chloride channel also increased during the weaning period and were upregulated by glucocorticoids. We conclude that there is a well-synchronized development of the many of the components that determine the concentrating capacity and that the low expression of AQP-2 is one of the limiting factors for low concentrating capacity in infants.